The paradox of heparin-induced thrombocytopenia: future anticoagulation.
Heparin and low molecular weight heparin agents are frequently administered to postoperative orthopedic patients. In patients with a history of heparin-induced thrombocytopenia, alternative anticoagulant agents to heparin for prophylaxis and treatment must be considered. Unfortunately, the data is limited in this patient population. Upon transitioning from heparin-induced thrombocytopenia treatment with direct thrombin inhibitors, argatroban, or lepirudin, careful consideration must be taken to avoid further thrombotic complications.
Taylor
Lisa M
LM
University of Kentucky Chandler Medical Center, Lexington, Ky, USA.
Smith
Kelly M
KM
D000906:Antibodies / Q000097:blood; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology; D019637:Orthopedic Procedures; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000145:classification; D013923:Thromboembolism / Q000517:prevention & control*; D013997:Time Factors
D000906:Antibodies; D000925:Anticoagulants; D007074:Immunoglobulin G; D006493:Heparin